PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Int Neuropsychol Soc. Author manuscript; available in PMC 2012 March 1.
Published in final edited form as:
PMCID: PMC3078700
NIHMSID: NIHMS261280

The Fate of the 0.5s: Predictors of 2-Year Outcome in Mild Cognitive Impairment

Abstract

Impairments in executive cognition (EC) may be predictive of incident dementia in patients with mild cognitive impairment (MCI). The present study examined whether specific EC tests could predict which MCI individuals progress from a Dementia Rating Scale (CDR) score of 0.5 to a score ≥1 over a 2-year period. Eighteen clinical and experimental EC measures were administered at baseline to 104 MCI patients (amnestic and non-amnestic, single- and multiple-domain) recruited from clinical and research settings. Demographic characteristics, screening cognitive measures and measures of everyday functioning at baseline were also considered as potential predictors. Over the two-year period, 18% of the MCI individuals progressed to CDR≥1, 73.1% remained stable (CDR=0.5), and 4.5% reverted to normal (CDR=0). Multiple-domain MCI participants had higher rates of progression to dementia than single-domain, but amnestic and non-amnestic MCIs had similar rates of conversion. Only three EC measures were predictive of subsequent cognitive and functional decline at the univariate level, but they failed to independently predict progression to dementia after adjusting for demographic, other cognitive characteristics, and measures of everyday functioning. Decline over 2 years was best predicted by informant ratings of subtle functional impairments and lower baseline scores on memory, category fluency and constructional praxis.

Keywords: Mild cognitive impairment, dementia, predictors of decline, executive cognition, Clinical Dementia Rating scale, MCI outcome

Older adults with mild cognitive impairment (MCI) are at substantially higher risk of dementia than cognitively normal elderly (5-10% for MCI versus 1-2% for normal elderly per year) (Mitchell & Shiri-Feshki, 2009; Petersen et al., 1999). Distinct clinical subtypes of MCI have been identified, the most extensively studied of which is amnestic MCI (aMCI). These are persons with memory complaints and psychometric evidence of memory decline, but intact overall cognitive function and generally preserved activities of daily living (Winblad et al., 2004). The latter is typically defined by a score no higher than 0.5 on the Clinical Dementia Rating (CDR) (Hughes, Berg, Danziger, Coben, & Martin, 1982). It has been suggested that aMCI has a less favorable prognosis than do the non-amnestic subtypes (naMCI) (Fischer et al., 2007; Morris & Cummings, 2005; Ravaglia et al., 2008). However, this is not a consistent finding (Mitchell, Arnold, Dawson, Nestor, & Hodges, 2009; Nordlund et al., 2009; Rozzini et al., 2007). In fact, many have reported that it is the presence of deficits in multiple cognitive domains (multiple-domain MCI [mdMCI]) rather than any specific domain that confers increased risk for dementia (Alexopoulos, Grimmer, Perneczky, Domes, & Kurz, 2006b; Baars et al., 2009; Manly et al., 2008; Rasquin, Lodder, Visser, Lousberg, & Verhey, 2005).

Although research has focused on the progression from MCI to dementia, reversion from MCI to normal cognition has also been documented, with rates ranging from 4% to 53% (Fisk, Merry, & Rockwood, 2003; Kryscio, Schmitt, Salazar, Mendiondo, & Markesbery, 2006; Larrieu et al., 2002; Ravaglia et al., 2006). Finally, a considerable number of individuals with MCI (11%-21%) remain stable when followed for up to 10 years (Fisk & Rockwood, 2005; Ganguli, Dodge, Shen, & DeKosky, 2004; Mitchell & Shiri-Feshki, 2009; Visser, Kester, Jolles, & Verhey, 2006). Thus, the outcome of MCI is varied.

Distinguishing the MCI individuals who are on a trajectory toward dementia from those with temporary or non-progressive cognitive difficulties is of increasing importance. There is some evidence that pharmacological intervention in MCI could delay the onset of dementia, or slow its progression (Aisen, 2008; Doody et al., 2009; Petersen et al., 2005; Yesavage et al., 2007). An accurate prognosis can help patients and their family plan for the care of the patient and make long-term financial decisions. Finally, identifying the “preclinical” stages of the disease could enhance our understanding of its early evolution, enabling us to study the pathological changes that occur before unambiguous symptoms emerge.

There are multiple approaches to the preclinical detection of a neurodegenerative disease, including use of brain imaging (Jack et al., 2008), blood and cerebrospinal fluid biomarkers (Mattsson et al., 2009), and genetic risk assessment (Caselli et al., 2009). The present study considers neurocognitive characteristics, since they are so easily attainable, widely available and usually part of the routine clinical assessment of people at risk for dementia.

There are several reasons to believe that deficits in executive cognition (EC) are particularly predictive of the development of dementia. First, they are relative common among individuals with MCI (Chen et al., 2000; Daly et al., 2000; Griffith et al., 2003) and present at the early stages of many diseases that cause dementia, such as Alzheimer’s disease, Parkinson’s disease or Huntington’s disease (Jacobs et al., 1995a; Mahieux et al., 1998; Woods & Troster, 2003). Second, many of the cognitive tests that others have reported to have prognostic value for dementia have substantial executive control requirements (Bondi et al., 1994; Elias et al., 2000; Jacobs et al., 1995b; Rapp & Reischies, 2005). Finally, several longitudinal studies suggest that EC measures are associated with subsequent decline (Albert, Moss, Tanzi, & Jones, 2001; Chen et al., 2000; Crowell, Luis, Vanderploeg, Schinka, & Mullan, 2002; Daly et al., 2000).

Executive cognition encompasses a wide range of abilities and processes (Miyake et al., 2000). An important limitation of previous studies investigating the ability of EC to predict incident dementia is that the sampling of EC was limited, typically to 2-3 tests (Albert et al., 2001; Amieva et al., 2004; Chen et al., 2000; Crowell et al., 2002; Daly et al., 2000; Tierney et al., 1996). Although including multiple EC measures as potential predictor variables may be statistically problematic, it is conceptually necessary when exploring the predictive utility of specific varieties of EC. In fact, patients with MCI have been found to be impaired on only specific aspects of EC (Brandt et al., 2009; Zhang, Han, Verhaeghen, & Nilsson, 2007).

Previous studies had other methodological limitations, as well. The participants’ outcome status was usually defined based on the presence or absence of a clinical diagnosis of dementia. Differences in diagnostic procedures or limiting the outcome to patients receiving the diagnosis of probable Alzheimer’s disease (i.e., excluding those with non-AD dementias) may have contributed to discrepant findings or may have limited the generalizability of previous findings. We circumvented this limitation by assessing cognitive and functional decline sufficient for a dementia diagnosis, but operationalized as a score ≥1 on the CDR. Furthermore, some previous studies have not sufficiently considered the role of demographic characteristics, such as age and education. Finally, it is unclear whether executive functioning predicts development of dementia above and beyond other factors, such as abilities to perform daily tasks at baseline or other aspects of cognition.

The purpose of the present study was to determine whether specific aspects of EC contribute uniquely to the detection of individuals who progress to dementia (CDR scores≥1) and whether they do so beyond and above other demographic, other cognitive and clinical characteristics. We examined the outcomes of patients with four subtypes of MCI over a two-year period and their association with baseline performances on 18 clinical and experimental EC tests. In addition, we examined whether specific MCI subtypes were associated with higher rates of cognitive and functional decline. Multiple-domain MCI patients were predicted to be at higher risk of decline than the other MCI subtypes.

Method

Participants

MCI groups

141 persons with MCI participated in the study. Most (70%) were recruited from the Johns Hopkins Alzheimer’s Disease Research Center (ADRC) and from other research studies. A smaller number of participants (30%) were referred from University clinics and physicians in the community. 90% of the participants were Caucasian and 10% were African-American.

Participants were diagnosed with MCI according to Petersen criteria (Petersen, 2004; Winblad et al., 2004). Inclusion criteria included a Mini-Mental State Exam (MMSE) score in the normal range (i.e., at or above the 20th percentile for age and education; range=26-30 in our sample) (Bravo & Hebert, 1997) and a global score of 0.5 on the CDR (Hughes et al., 1982). In addition, participants were required to perform at or below 1.5 standard deviations below the mean for age and education (i.e., 6.7th percentile), according to published norms, on one or more of the following screening tests: Logical Memory (story A) of the Wechsler Memory Scale-Revised (WMS-R) (Wechsler, 1987), the 30-item version of the Boston Naming Test (Brandt et al., 1989; Goodglass, 1983), word list generation (for the letters FAS [Phonemic Fluency] and the semantic categories animals and vegetables [Category Fluency]) (Rascovsky, Salmon, Hansen, Thal, & Galasko, 2007) and clock drawing to request (Rouleau, Salmon, Butters, Kennedy, & McGuire, 1992). Finally, each participant was required to have a study partner who could provide information about his/her functional abilities.

Exclusion criteria were any history of major mental illness, CNS disorder or active systemic illness (e.g., cancer). Volunteers with past or present depression were not excluded since depression is very common in MCI and may be related to outcome (Jorm, 2001; Lyketsos et al., 2002).

141 participants received baseline neuropsychological evaluations, fulfilled our criteria for MCI, and were subsequently assigned to one of four MCI subgroups: amnestic single domain (AS; n=36), amnestic multiple domain (AM; n=45), non-amnestic single domain (NAS; n=26), and non-amnestic multiple domain (NAM; n=17). The criteria for subgroup membership were based on performance on the four cognitive screening tests described above; see Brandt et al. (2009) for details. Out of the 141 participants with a baseline assessment, 104 had a follow-up examination after 2 years. 5 MCI participants were deceased by the second evaluation, 15 refused participation and 9 were not reachable (attrition rate per year=10.9%). Eight participants had not yet received follow-up evaluations at the time of the analysis and were therefore excluded. The final sample included 30 AS, 38 AM, 23 NAS, and 13 NAM patients. Additional details regarding the study participants have been published previously (Brandt et al., 2009).

Group outcome

Participant status two years after baseline assessment was assessed with a repeat CDR interview with the study partner. Each participant had the same study partner for both CDR interviews, except 9 participants, whose initial informants were not available for the follow-up interview. For the purposes of this study, subjects are described as having progressed to dementia if they had a CDR global score ≥1 at follow-up. If they obtained a CDR global score of 0, they are described as having reverted to normal. If they obtained a 0.5 at follow-up, they are described as still having MCI.

Procedure

Executive function measures

Eighteen EC measures representing six conceptually distinct domains of EC were administered to the participants. Most of the EC measures are from widely-used, standardized tests that were administered and scored according to standard instructions. The tests and the specific measure selected from each one are shown in Table 1. In addition, the following three experimental tasks were developed specifically for the present study:

Table 1
Summary of tests of executive function (Brandt et al., 2009)

Completions & Corrections Test (Manning & Brandt, 2006): In this task, the examinee is read 12 altered idiomatic expressions and asked to repeat each one verbatim. Five of the phrases are meant to induce errors that are either completions or extensions of the original (AHip, Hip,…@), while the remaining seven are meant to induce corrections (AThe tooth, the whole tooth, and nothing but the tooth.@). Number of phrases repeated verbatim (i.e., not corrected or completed) is recorded.

Tic-Tac-Toe (Brandt et al., 2009; Crowley & Siegler, 1993): A standardized version of this well-known paper-and-pencil game was developed specifically for the present study. Sixteen trials were played, with the examiner and participant alternating who moves first. On half the trials on which the examiner started, s/he purposely made a suboptimal initial move (i.e., one other than a corner), thereby allowing the patient an advantage. The examinee is credited one point for every trial s/he wins, and is debited one point for every loss; ties result in no change in score.

Experimental Judgment Test (Brandt et al., 2009): This task requires that the subject estimate three attributes of the examiner, specifically his/her age, height, and weight. Score on the test is the mean percent deviation from actual values on the three items.

Measures of functional status

Three informant-reported ratings of daily functioning were included in the present study, since even mild restriction in instrumental activities of daily living (IADL) has been found to be associated with a much higher risk of progression to dementia and a much lower chance of reversibility of cognitive deficit (Peres et al., 2006). The study partners’ responses on questionnaires assessing functional status were not considered in the calculation of the CDR scores.

The Activities of Daily Living-Prevention Instrument developed by the Alzheimer’s Disease Cooperative Study Committee (ADCS ADL-PI) (Ferris et al., 2006; Galasko et al., 2006) consists of 15 items assessing performance on complex activities of daily living rated on a 3-point scale (0=‘no difficulty’ to 2=‘a lot of difficulty’). The sum of ratings on the 15 functional items constitutes the score.

The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) (Jorm & Jacomb, 1989) assesses changes in an elderly subject’s everyday cognitive abilities as manifested in daily life. Twenty six cognitive activities of daily life are described and rated on a 5-point scale compared to 10 years previously (1=‘much better’ to 5=‘much worse’). The mean of the 26 ratings was used in our analyses.

The Dysexecutive Questionnaire (DEX) (Wilson, 1996) measures behavioral changes evident in daily functioning that result from a dysexecutive syndrome. Twenty statements describing common problems of everyday life are rated on a 5-point scale according to their frequency (0=‘never’ to 4=‘very often’).

The Johns Hopkins University Institutional Review Board fully reviewed and approved the study protocol. Written informed consent was obtained from all participants and their study partners.

Statistical analysis

Statistical analyses were performed using PASW 17. One-way analysis of variance (ANOVAs) and chi-square (χ2) were used to compare the four groups on demographic and clinical characteristics at baseline. χ2 was further used to test the association of participants’ group and subgroup membership (aMCI vs. naMCI; single domain MCI [sdMCI] vs. multiple domain MCI [mdMCI]) at baseline with the frequency of development of dementia at the follow up visit. In addition, we compared the baseline characteristics and performances of those who progressed to a CDR global score of 1 or more with the performances of those who remained at 0.5.

The ability of demographic and clinical characteristics, the cognitive screening tests and the EC measures to predict progression from CDR=0.5 to CDR≥1 was assessed with univariate logistic regression analyses. Stable MCI was the reference group in all analyses. Variables significantly predicting the MCI outcome in the univariate regression models were then entered in a hierarchical logistic regression model together with demographic characteristics. The hierarchical regression model was developed to determine whether EC predicts outcome in MCI patients above and beyond demographic, clinical, and other cognitive factors. Therefore, in the first block, demographic variables (age, education, sex) were forced to enter; in the second block, measures of everyday functioning that were significantly associated with cognitive status at 2-year follow-up could enter; in the third block, the screening battery tests that predicted progression to dementia at the univariate level could enter; finally, in the fourth block, the EF variables that were significant predictors at the univariate level were allowed to enter. Variables in each block were entered in a forward stepwise fashion, using the likelihood ratio criterion.

A receiver operating characteristic (ROC) curve was plotted to illustrate the sensitivity and specificity of the predictive model that resulted from the hierarchical regression analysis.

An omnibus forward stepwise logistic regression model, using the likelihood ratio criterion, was computed to test the predictive ability of the variables that were significant predictors of progression at the univariate level when entered simultaneously. The purpose of this omnibus regression analysis was to test the prognostic value of EC in the context of all other clinical and cognitive measures.

Due to sample size constraints, all the regression analyses were performed within the pooled MCI sample, rather than within the subgroups separately. In the present paper, although we describe all three possible outcomes of MCI patients (reversion to normal, stable MCI and progression to dementia), we modeled only progression to dementia due to the small number of the MCI individuals who reverted to normal (i.e., only 9 persons scored 0 on the CDR at the two-year follow-up).

Results

Demographic and clinical baseline characteristics

The demographic and clinical characteristics of the participants at baseline are summarized in Table 2. The groups did not differ in age (F(3,104)=2.06, p>.05) or education F(3,104)=2.03, p>.05), but had different sex distributions (χ2=10.06, df=3, p=.018); women predominated in the NAM group. The groups had equivalent MMSE scores (F(3,104)=.91, p>.05), and self-reported symptoms of depression (F(3,104)=.90, p>.05), but their CDR sum of boxes (CDR-SB) differed (F(3,104)=5.12, p=.002), with AS patients having lower scores (less impairment) than the three other groups.

Table 2
Demographic and baseline clinical characteristics of the participants who had two-year follow-ups. All participants had CDR global scores of 0.5 at first visit. Means + standard errors, unless otherwise noted. For continuously distributed variables, effect ...

Group outcomes

From the 104 MCI patients at baseline, 76 remained stable (73.1%), 19 progressed to CDR≥1 (18%, or 9% per year) and 9 reverted to CDR=0 (9%, or 4.5% per year) at two-year follow-up (see Figure 1). The presence of impairment in memory (i.e., aMCI vs. naMCI) was not associated with progression to dementia (χ2=1.97 df=2, p>.05), whereas the presence of impairments in multiple domains (i.e., sdMCI vs. mdMCI), regardless of the specific domains involved, was so associated (χ2=18.34, df=2, p<.001). More specifically, of the 51 mdMCI individuals at baseline, 16 (31%) progressed to dementia over a two-year period, compared to only 3 out of 53 (6%) sdMCI patients. None of the mdMCI patients reverted to normal, whereas 9 (17%) of the sdMCI did.

Figure 1
Clinical status at 2-year follow up as a function of group at entry.

Detailed information on the baseline and follow-up neuropsychological test scores and clinical characteristics of the participants by MCI subgroup is presented in Table 3.

Table 3
Baseline and follow-up scores and clinical characteristics of study participants by subgroup over the 2-year interval. Means (± SE)

Baseline demographic, clinical and cognitive characteristics of groups defined by outcome status

To further explore the outcome of the MCI patient groups, we compared the baseline characteristics and performances on the screening measures of those who converted to dementia (n=19) with those who remained MCI (n=76). The groups did not differ on age (F(1,92)=2.14, p=.147), years of education (F(1,92)=0.02, p=.890), sex distribution (χ2=0.28, df=1, p=.595), MMSE scores (F(1,92)=3.50, p=.065) or ratings on the CDR-SB (F(1,92)=2.83, p=.096). However, those who developed dementia had lower initial scores on the Category Fluency Test (F(1,92)=8.59, p=.004), the Clock Drawing Test (F(1,92)=4.82, p=.031), and the delayed recall of Logical Memory of the WMS-R (F(1,92)=7.95, p=.006) than those who remained MCI after 2 years.

Predictors of progression to dementia in MCI

Univariate logistic regression models

Univariate logistic regression models were used to examine the predictive value for dementia of each measure separately. Demographic characteristics in our sample were not associated with the CDR score after two years. However, ratings on specific measures of everyday functioning, in particular the ADCS ADL-PI and the IQCODE, predicted progression to CDR≥1 at the follow-up visit. Higher scores on both measures (indicating worse functioning) were associated with increase in the likelihood of developing dementia at two years. In addition, lower scores on specific cognitive screening tests at baseline —the Clock Drawing Test, the delayed recall of the WMS-R Logical Memory, and the Category Fluency— were associated with higher likelihood of having dementia at two years. From the 18 executive function measures, only three were predictive of decline over the two-year period. Lower scores on the Hayling Test, the Alternate Uses Test, and the Verbal Concept Attainment Test were associated with higher likelihood of having a CDR score ≥1. Table 4 presents the results of the univariate logistic regression analyses for the variables that significantly predicted CDR score at the follow-up visit.

Table 4
Univariate associations between baseline demographic, clinical and neuropsychological characteristics and progression to dementia (CDR≥1) over a 2-year follow-up period

Hierarchical logistic regression model

Demographic characteristics (Block 1) were forced to enter into the model first. Among the measures of everyday functioning (Block 2), only ADCS ADL-PI score entered, accounting for 12.3% of the variance in the outcome. From the screening battery (Block 3), WMS-R Logical Memory (delayed recall) entered at step 1, Category Fluency at step 2 and Clock Drawing Test at step 3, explaining an additional 24.9% of variance. Beyond this, none of the EC measures contributed independently to the prediction of progression from MCI to dementia. Together, the four test variables in the model and the demographic characteristics accounted for 41.3% of the variance in the outcome. Overall classification accuracy of the model was 84.7% (see Table 5).

Table 5
Hierarchical logistic regression predicting functional/cognitive status (MCI or dementia) at 2 year follow-up as a function of demographic characteristics, and baseline clinical and cognitive factors

Omnibus logistic regression model

The logistic regression analysis with entry of all variables that were significant in the univariate analysis together in a stepwise fashion resulted in findings similar to those of the hierarchical regression model. Specifically, the ADCS ADL-PI entered the model first (accounting for 12.8% of the variance of the outcome; OR=1.179, 95%CI:1.043-1.333, p=.009), followed by the WMS-R Logical Memory (11.6% variance explained; OR=.820, 95%CI:0.697-.963, p=.016), then the Category Fluency (12.2% variance explained; OR=.880, 95%CI:0.790-0.981, p=.021), and the Clock Drawing Test (6.7% variance explained; OR=.623, 95%CI:0.399-0.972, p=.037). No demographic characteristic and no EC measure entered the model. These predictors explained a total of 40.3% of the variance of the outcome.

Sensitivity and specificity of the prediction models

ROC analysis of the “probability of progression to CDR≥1” score that results from the combined predictors of the hierarchical regression model indicated high discriminative accuracy (see Figure 2; AUC=.847, CIs=.742-.953). Using a probability for dementia cutoff value of 0.146, the model yielded a sensitivity of 0.94 and a specificity of 0.71. Thus, 94% of the MCI patients who progressed to dementia had a probability score higher than 0.146, whereas 71% of stable MCI patients had a probability score of less than 0.146.

Figure 2
ROC curve for the combined predictors of the hierarchical model for discrimination of stable MCI patients and those who progressed to dementia.

Discussion

The present study is, to our knowledge, the first systematic and comprehensive study of the predictive value of EC for the outcome of MCI patients. During a two year period, 18% of the MCI individuals progressed to dementia, corresponding to an annual rate of 9%. The majority of the patients remained stable over time, whereas 9% returned to normal cognitive status. We found that MCI individuals with impairments in multiple domains at baseline were at higher risk of decline over the 2-year period than those with impairment in a single domain (Alexopoulos et al., 2006b; Loewenstein et al., 2009; Manly et al., 2008; Mitchell et al., 2009; Nordlund et al., 2009). One plausible explanation is that mdMCI might represent a more advanced stage of the disease process than sdMCI (Alexopoulos, Grimmer, Perneczky, Domes, & Kurz, 2006a). It is also possible that some sdMCI individuals might have always performed poorly in a specific cognitive domain (Petersen et al., 1999) or they did so temporarily in response to one or more stressful life events, such as illness or death of a family member. Regardless of the explanation, and considering the fact that only sdMCI reverted to normal, it appears that an isolated cognitive impairment in an elderly person may be relatively benign.

Whether the presence of memory impairments increases the risk for subsequent dementia among persons with MCI is controversial. As in several previous studies, we found that memory impairment was not specifically associated with an increased rate of progression to dementia (Mitchell et al., 2009; Nordlund et al., 2009). However, others concluded that MCI individuals with isolated memory impairment were more likely to progress to dementia than those with a single non-memory impairment or even those with impairments in multiple domains (Ravaglia et al., 2006; Yaffe, Petersen, Lindquist, Kramer, & Miller, 2006). Manly et al. (2008) found that MCI individuals with memory impairments are at highest risk, especially when other cognitive deficits are present. Of note, a large community-based study concluded that although a high-risk group for dementia, aMCI is unstable and heterogeneous; significant proportions remain stable or improve on long-term follow ups (Ganguli et al., 2004).

A major finding of the present study is the limited predictive power of EC measures for the development of dementia. Only three out of eighteen EC measures —the Alternate Uses Test, the Hayling Test and the Verbal Concept Attainment Test— were significantly associated with incident dementia at the univariate level. These tests assess spontaneous flexibility and generativity, inhibition of prepotent responses and concept rule learning, respectively. However, all three tests also rely on semantic memory. Both Hayling and Alternate Uses Test require the participant to inhibit a semantically constrained response and the Verbal Concept Attainment Test is very highly correlated with verbal tests such as the Wechsler Adult Intelligence Scale (WAIS) Vocabulary (Belleville, Rouleau, & Van der Linden, 2006; Bornstein, 1982). Thus, their dependence on semantic memory might also contribute to their sensitivity to predict cognitive decline and dementia.

Although these three tests were found to be predictive at the univariate level, none of them added to the predictive ability of a model that first considered demographic characteristics, cognitive screening tests, and everyday functioning. Our observed lack of predictive value of EC over other measures is in contrast to the reported findings of several longitudinal studies. Specifically, measures of set-shifting and sequencing (Albert et al., 2001; Chen et al., 2000), attention (Amieva et al., 2004; Tierney et al., 1996), and abstract reasoning (Elias et al., 2000) have been identified as predictors of incident dementia in MCI patients. However, in none of these studies was the prognostic value of EC examined after controlling for other factors (i.e., demographic characteristics, non-executive cognition, and everyday functioning). Manly et al. (2008) reported that MCI patients with isolated executive impairment were less likely to have underlying AD neuropathology and progress to dementia than those with an isolated memory or isolated language impairment. Similarly, Farias et al. (2009) indicated that executive dysfunction was not associated with an increased risk of progression to dementia over other factors such as age, education, clinic recruitment source, and functional status.

There are many confounding factors when one is trying to assess the predictive value of neurocognitive measures at baseline for incident dementia. One of the parameters that has not been adequately emphasized is that the predictive value of a measure is conditional on the other measures in the model. Differences in the variables included in the predictive model might explain why, for example, Trail Making Test has been found to be the strongest predictor in several studies (Albert et al., 2001; Chen et al., 2000; Crowell et al., 2002; Daly et al., 2000), but not in others (Grober et al., 2008; Mitchell et al., 2009). Our results suggest that the predictive utility of EC over other cognitive measures might have been overestimated. An alternative interpretation is that most cognitive measures, especially those of any complexity, have substantial executive requirements (Salthouse, Atkinson, & Berish, 2003), and they consequently restrict the unique variance that “pure” EC measures can account for. Indeed, both the Clock Drawing Test and the Category Fluency Test rely on executive skills such as planning, search strategies, self-monitoring, and organization (Henry & Crawford, 2004; Lewis & Miller, 2007; Lowery et al., 2003). Finally, other factors, such as the interval between the baseline and the follow-up assessment, might affect the sensitivity of a test to detect decline, since it can be related to the stage of the potential preclinical course of the MCI patient (Grober et al., 2008).

Among all the cognitive measures, the delayed recall of the Logical Memory, the Category Fluency and the Clock Drawing Test were the most sensitive predictors of MCI outcome. Impairment in episodic memory and semantic fluency have been shown to be among the earliest cognitive changes that are consistent over very long follow-ups in contrast to deficits in other cognitive domains, which might appear at early stages but tend to be unstable over time (Hodges, Erzinclioglu, & Patterson, 2006). The Category Fluency Test and the Clock Drawing Test implicate executive processes but are also dependent on intact semantic memory (Henry & Crawford, 2004; Hodges, Salmon, & Butters, 1992; Lowery et al., 2003). There is also considerable evidence that verbal generativity and “idea density” is significantly compromised several years before dementia is diagnosed (Oulhaj, Wilcock, Smith, & de Jager, 2009; Riley, Snowdon, Desrosiers, & Markesbery, 2005; Snowdon et al., 1996). In addition, semantic fluency appears dependent on the integrity of the temporal neocortex, a brain region proportionately affected very early in the Alzheimer’s disease (Arnold, Hyman, Flory, Damasio, & Van Hoesen, 1991; Baldo, Schwartz, Wilkins, & Dronkers, 2006; Henry & Crawford, 2004).

Changes in daily functioning measured with the ADCS ADL-PI, and the IQCODE at baseline were also found to have significant prognostic value for the MCI outcome. ADCS ADL-PI measures minor changes in functional status that occur in the transition from cognitively normal to MCI or early dementia and IQCODE is considered “a measure of the disablement caused by cognitive decline” (Jorm et al., 1996) p. 137). Unlike the cognitive tests administered at baseline, these are measures of change or deterioration. Thus, these findings may simply indicate that prior change predicts future change. Of note, both measures had only weak correlations with the EC measures (ranging from r=−.009 to r=−.232) and their exclusion from the regression model did not change the contribution of EC measures for the prediction of MCI outcome. Several other studies have documented that worse ratings on functional measures at baseline are strongly related to a diagnosis of dementia at follow-up (Daly et al., 2000; Dickerson, Sperling, Hyman, Albert, & Blacker, 2007; Morris & Cummings, 2005; Peres et al., 2006; Rozzini et al., 2007). Finally, the increased risk of dementia in clinic- versus population-based studies appears to be explained by the greater baseline functional impairment in the MCI patients recruited from clinics (Farias, Mungas, Reed, Harvey, & DeCarli, 2009). Our results underline further the necessity to carefully assess everyday functioning in persons at risk for dementia.

The present study has certain limitations. First, although our MCI sample is relatively large, it is probably not adequate for the number of predictors we tested. We recognize that our analyses are rather exploratory, but the consistency of our findings using different regression models supports the robustness of our conclusions. Second, our criteria for defining MCI may be questioned, since there is no consensus on how the Petersen/Mayo criteria should be operationalized. However, we applied both clinical criteria (interview with an informant, yielding a CDR score of 0.5), as well as psychometric criteria (based on well-recognized neuropsychological procedures). Similar methodology has been implemented in several other studies (Alexopoulos et al., 2006b; Dickerson et al., 2007; Grundman et al., 2004; Storandt, Grant, Miller, & Morris, 2006) and conforms to the current standard for the diagnosis of MCI (Petersen, 2004). Third, we operationalized the development of dementia as progression from CDR=0.5 to CDR≥1. Participants were not formally evaluated by a clinician in this study (although many were so-evaluated and diagnosed in other research studies or clinics) and we cannot exclude the possibility that a participant could be assigned a global CDR score ≥1 for other reasons (i.e, caregiver distress). However, CDR has been used in numerous studies to identify both MCI and dementia cases (Daly et al., 2000; DeCarli et al., 2004; Storandt et al., 2006) and neuropathological findings have validated the utility of CDR scores to detect the presence of AD (Berg, McKeel, Miller, Baty, & Morris, 1993; Morris, 1997).

In summary, our 2-year follow-up of MCI individuals confirmed previous findings that persons with multiple cognitive impairments are at higher risk for functional decline than those with isolated deficits. EC has limited incremental validity as a predictor of which MCI individuals progress from CDR=0.5 to CDR≥1. However, other cognitive measures (Logical Memory of the WMS-R, Category Fluency and the Clock Drawing Test) and measures of everyday functioning (ADCS ADL-PI) can predict the fate of the 0.5s with reasonably high accuracy. It still remains unclear whether EC can predict which MCI individuals revert to normal cognitive status, when followed over time.

Acknowledgments

The authors thank Laura Wulff, Ph.D., Chiadi Onyike, M.D., Marilyn Albert, Ph.D., and the staff and participants of the Johns Hopkins Alzheimer’s Disease Research Center. Eleanor Neijstrom, M.S., Jaclyn Samek, B.S., and Kevin Manning, M.S. collected the data. This study was supported by the National Institute on Aging (J.B., grant AG-005146).

Footnotes

No conflicts of interest exist.

References

  • Aisen PS. Treatment for MCI: is the evidence sufficient? Neurology. 2008;70(22):2020–2021. [PubMed]
  • Albert MS, Moss MB, Tanzi R, Jones K. Preclinical prediction of AD using neuropsychological tests. Journal of the International Neuropsychological Society. 2001;7(05):631–639. [PubMed]
  • Alexopoulos P, Grimmer T, Perneczky R, Domes G, Kurz A. Do all patients with mild cognitive impairment progress to dementia? Journal of the American Geriatric Society. 2006a;54(6):1008–1010. [PubMed]
  • Alexopoulos P, Grimmer T, Perneczky R, Domes G, Kurz A. Progression to dementia in clinical subtypes of mild cognitive impairment. Dementia and Geriatric Cognitive Disorders. 2006b;22(1):27–34. [PubMed]
  • Amieva H, Letenneur L, Dartigues JF, Rouch-Leroyer I, Sourgen C, D’Alchee-Biree F, Fabrigoule C. Annual rate and predictors of conversion to dementia in subjects presenting mild cognitive impairment criteria defined according to a population-based study. Dementia and Geriatric Cognitive Disorders. 2004;18(1):87–93. [PubMed]
  • Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer’s disease. Cerebral Cortex. 1991;1(1):103–116. [PubMed]
  • Baars MA, van Boxtel MP, Dijkstra JB, Visser PJ, van den Akker M, Verhey FR, Jolles J. Predictive value of mild cognitive impairment for dementia. The influence of case definition and age. Dementia and Geriatric Cognitive Disorders. 2009;27(2):173–181. [PubMed]
  • Baldo JV, Schwartz S, Wilkins D, Dronkers NF. Role of frontal versus temporal cortex in verbal fluency as revealed by voxel-based lesion symptom mapping. Journal of the International Neuropsychological Society. 2006;12(06):896–900. [PubMed]
  • Bechara A, Damasio H, Tranel D, Anderson SW. Dissociation of working memory from decision making within the human prefrontal cortex. The Journal of Neuroscience. 1998;18(1):428–437. [PubMed]
  • Belleville S, Rouleau N, Van der Linden M. Use of the Hayling task to measure inhibition of prepotent responses in normal aging and Alzheimer’s disease. Brain and Cognition. 2006;62(2):113–119. [PubMed]
  • Berg L, McKeel DW, Jr, Miller JP, Baty J, Morris JC. Neuropathological indexes of Alzheimer’s disease in demented and nondemented persons aged 80 years and older. Archives of Neurology. 1993;50(4):349–358. [PubMed]
  • Bondi MW, Monsch AU, Galasko D, Butters N, Salmon DP, Delis DC. Preclinical cognitive markers of dementia of the Alzheimer type. Neuropsychology. 1994;8(3):374–384.
  • Bornstein RA. A factor analytic study of the construct validity of the verbal concept attainment test. Journal of Clinical Neuropsychology. 1982;4(1):43–50. [PubMed]
  • Brandt J, Aretouli E, Neijstrom E, Samek J, Manning K, Albert MS, Bandeen-Roche K. Selectivity of executive function deficits in mild cognitive impairment. Neuropsychology. 2009;23(5):607–618. [PMC free article] [PubMed]
  • Brandt J, Mellits ED, Rovner B, Gordon B, Selnes OA, Folstein MF. Relation of age at onset and duration of illness to cognitive functioning in Alzheimer’s disease. Cognitive and Behavioral Neurology. 1989;2(2):93–101.
  • Bravo G, Hebert R. Age- and education-specific reference values for the Mini-Mental and modified Mini-Mental State Examinations derived from a non-demented elderly population. International Journal of Geriatric Psychiatry. 1997;12(10):1008–1018. [PubMed]
  • Brugger P, Monsch AU, Salmon DP, Butters N. Random number generation in dementia of the Alzheimer type: a test of frontal executive functions. Neuropsychologia. 1996;34(2):97–103. [PubMed]
  • Burgess PW, Shallice T. The Hayling and Brixton Tests Manual. Thames Valley Test Company Limited; Bury St. Edmunds, England: 1997.
  • Caselli RJ, Dueck AC, Osborne D, Sabbagh MN, Connor DJ, Ahern GL, Reiman EM. Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. The New England Journal of Medicine. 2009;361(3):255–263. [PMC free article] [PubMed]
  • Chen P, Ratcliff G, Belle SH, Cauley JA, DeKosky ST, Ganguli M. Cognitive tests that best discriminate between presymptomatic AD and those who remain nondemented. Neurology. 2000;55(12):1847–1853. [PubMed]
  • Crowell TA, Luis CA, Vanderploeg RD, Schinka JA, Mullan M. Memory patterns and executive functioning in mild cognitive impairment and Alzheimer’s disease. Aging, Neuropsychology, and Cognition. 2002;9(4):288–297.
  • Crowley K, Siegler RS. Flexible strategy use in young children’s tic-tac-toe. Cognitive Science. 1993;17(4):531–561.
  • Daly E, Zaitchik D, Copeland M, Schmahmann J, Gunther J, Albert M. Predicting conversion to Alzheimer disease using standardized clinical information. Archives of Neurology. 2000;57(5):675–680. [PubMed]
  • DeCarli C, Mungas D, Harvey D, Reed B, Weiner M, Chui H, Jagust W. Memory impairment, but not cerebrovascular disease, predicts progression of MCI to dementia. Neurology. 2004;63(2):220–227. [PMC free article] [PubMed]
  • Delis DC, Kaplan E, Kramer JH. Delis-Kaplan Executive Function System examiner’s manual. Psychological Corporation; San Antonio, TX: 2001.
  • Dickerson BC, Sperling RA, Hyman BT, Albert MS, Blacker D. Clinical prediction of Alzheimer disease dementia across the spectrum of mild cognitive impairment. Archives of General Psychiatry. 2007;64(12):1443–1450. [PMC free article] [PubMed]
  • Doody RS, Ferris SH, Salloway S, Sun Y, Goldman R, Watkins WE, Murthy AK. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology. 2009;72(18):1555–1561. [PubMed]
  • Elias MF, Beiser A, Wolf PA, Au R, White RF, D’Agostino RB. The preclinical phase of Alzheimer disease: A 22-year prospective study of the Framingham cohort. Archives of Neurology. 2000;57(6):808–813. [PubMed]
  • Farias ST, Mungas D, Reed BR, Harvey D, DeCarli C. Progression of mild cognitive impairment to dementia in clinic- vs community-based cohorts. Archives of Neurology. 2009;66(9):1151–1157. [PMC free article] [PubMed]
  • Ferris SH, Aisen PS, Cummings J, Galasko D, Salmon DP, Schneider L, Thal LJ. ADCS Prevention Instrument Project: overview and initial results. Alzheimer Disease and Associated Disorders. 2006;20(4):S109–123. [PubMed]
  • Fischer P, Jungwirth S, Zehetmayer S, Weissgram S, Hoenigschnabl S, Gelpi E, Tragl KH. Conversion from subtypes of mild cognitive impairment to Alzheimer dementia. Neurology. 2007;68(4):288–291. [PubMed]
  • Fisk JD, Merry HR, Rockwood K. Variations in case definition affect prevalence but not outcomes of mild cognitive impairment. Neurology. 2003;61(9):1179–1184. [PubMed]
  • Fisk JD, Rockwood K. Outcomes of incident mild cognitive impairment in relation to case definition. Journal of Neurology, Neurosurgery, & Psychiatry. 2005;76(8):1175–1177. [PMC free article] [PubMed]
  • Galasko D, Bennett DA, Sano M, Marson D, Kaye J, Edland SD. ADCS Prevention Instrument Project: assessment of instrumental activities of daily living for community-dwelling elderly individuals in dementia prevention clinical trials. Alzheimer Disease and Associated Disorders. 2006;20(3):S152–169. [PubMed]
  • Ganguli M, Dodge HH, Shen C, DeKosky ST. Mild cognitive impairment, amnestic type: an epidemiologic study. Neurology. 2004;63(1):115–121. [PubMed]
  • Goodglass H, Kaplan E. Boston Diagnostic Aphasia Examination. Lea and Febiger; Philadelphia: 1983.
  • Griffith HR, Belue K, Sicola A, Krzywanski S, Zamrini E, Harrell L, Marson DC. Impaired financial abilities in mild cognitive impairment: a direct assessment approach. Neurology. 2003;60(3):449–457. [PubMed]
  • Grober E, Hall CB, Lipton RB, Zonderman AB, Resnick SM, Kawas C. Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer’s disease. Journal of the International Neuropsychological Society. 2008;14(02):266–278. [PMC free article] [PubMed]
  • Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, Thal LJ. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Archives of Neurology. 2004;61(1):59–66. [PubMed]
  • Guilford JP, Christensen PR, Merryfield PR, Wilson RC. Alternate uses, Form B, Form C; manual of instructions and interpretations. Sheridan Psychological Services Inc.; Orange, CA: 1978.
  • Henry JD, Crawford JR. A meta-analytic review of verbal fluency performance following focal cortical lesions. Neuropsychology. 2004;18(2):284–295. [PubMed]
  • Hodges JR, Erzinclioglu S, Patterson K. Evolution of cognitive deficits and conversion to dementia in patients with mild cognitive impairment: a very-long-term follow-up study. Dementia and Geriatric Cognitive Disorders. 2006;21(5-6):380–391. [PubMed]
  • Hodges JR, Salmon DP, Butters N. Semantic memory impairment in Alzheimer’s disease: Failure of access or degraded knowledge? Neuropsychologia. 1992;30(4):301–314. [PubMed]
  • Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. British Journal of Psychiatry. 1982;140:566–572. [PubMed]
  • Jack CR, Jr., Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, Weiner MW. The Alzheimer’s Disease Neuroimaging Initiative (ADNI): MRI methods. Journal of Magnetic Resonance Imaging. 2008;27(4):685–691. [PMC free article] [PubMed]
  • Jacobs DM, Marder K, Cote LJ, Sano M, Stern Y, Mayeux R. Neuropsychological characteristics of preclinical dementia in Parkinson’s disease. Neurology. 1995a;45(9):1691–1696. [PubMed]
  • Jacobs DM, Sano M, Dooneief G, Marder K, Bell KL, Stern Y. Neuropsychological detection and characterization of preclinical Alzheimer’s disease. Neurology. 1995b;45(5):957–962. [PubMed]
  • Jorm AF. History of depression as a risk factor for dementia: an updated review. Australian and New Zealand Journal of Psychiatry. 2001;35(6):776–781. [PubMed]
  • Jorm AF, Broe GA, Creasey H, Sulway MR, Dent O, Fairley MJ, Tennant C. Further data on the validity of the informant questionnaire on cognitive decline in the elderly (IQCODE) International Journal of Geriatric Psychiatry. 1996;11(2):131–139.
  • Jorm AF, Jacomb PA. The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): socio-demographic correlates, reliability, validity and some norms. Psychological Medicine. 1989;19(4):1015–1022. [PubMed]
  • Koss E, Patterson MB, Mack JL, Smyth KA, Whitehouse PJ. Reliability and validity of the Tinkertoy Test in evaluating individuals with Alzheimer’s disease. Clinical Neuropsychologist. 1998;12(3):325–329.
  • Kryscio RJ, Schmitt FA, Salazar JC, Mendiondo MS, Markesbery WR. Risk factors for transitions from normal to mild cognitive impairment and dementia. Neurology. 2006;66(6):828–832. [PubMed]
  • Larrieu S, Letenneur L, Orgogozo JM, Fabrigoule C, Amieva H, Le Carret N, Dartigues JF. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology. 2002;59(10):1594–1599. [PubMed]
  • Lewis MS, Miller LS. Executive control functioning and functional ability in older adults. The Clinical Neuropsychologist. 2007;21:274–285. [PubMed]
  • Lezak MD. The problem with assessing executive functions. International Journal of Psychology. 1982;17:281–297.
  • Loewenstein DA, Acevedo A, Small BJ, Agron J, Crocco E, Duara R. Stability of different subtypes of mild cognitive impairment among the elderly over a 2- to 3-year follow-up period. Dementia and Geriatric Cognitive Disorders. 2009;27(5):418–423. [PMC free article] [PubMed]
  • Lowery N, Giovanni L, Mozley LH, Arnold SE, Bilker WB, Gur RE, Moberg PJ. Relationship between clock-drawing and neuropsychological and functional status in elderly institutionalized patients with schizophrenia. American Journal of Geriatric Psychiatry. 2003;11(6):621–628. [PubMed]
  • Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. Journal of the American Medical Association. 2002;288(12):1475–1483. [PubMed]
  • Mahieux F, Fenelon G, Flahault A, Manifacier MJ, Michelet D, Boller F. Neuropsychological prediction of dementia in Parkinson’s disease. Journal of Neurology, Neurosurgery, & Psychiatry. 1998;64(2):178–183. [PMC free article] [PubMed]
  • Manly JJ, Tang MX, Schupf N, Stern Y, Vonsattel JP, Mayeux R. Frequency and course of mild cognitive impairment in a multiethnic community. Annals of Neurology. 2008;63(4):494–506. [PMC free article] [PubMed]
  • Manning KJ, Brandt J. Completions and Corrections as a test of executive control. International Neuropsychological Society; Boston, Massachusetts: Feb, 2006.
  • Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Blennow K. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. Journal of the American Medical Association. 2009;302(4):385–393. [PubMed]
  • Mitchell A, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia--meta-analysis of 41 robust inception cohort studies. Acta Psychiatrica Scandinavica. 2009;119(4):252–265. [PubMed]
  • Mitchell J, Arnold R, Dawson K, Nestor PJ, Hodges JR. Outcome in subgroups of mild cognitive impairment (MCI) is highly predictable using a simple algorithm. Journal of Neurology. 2009;256(9):1500–1509. [PubMed]
  • Miyake A, Friedman NP, Emerson MJ, Witzki AH, Howerter A, Wager TD. The unity and diversity of executive functions and their contributions to complex “frontal lobe” tasks: a latent variable analysis. Cognitive Psychology. 2000;41(1):49–100. [PubMed]
  • Morris JC. Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. International Psychogeriatrics. 1997;9(1):173–176. discussion 177-178. [PubMed]
  • Morris JC, Cummings J. Mild cognitive impairment (MCI) represents early-stage Alzheimer’s disease. Journal of Alzheimer’s Disease. 2005;7(3):235–239. [PubMed]
  • Nordlund A, Rolstad S, Klang O, Edman A, Hansen S, Wallin A. Two year outcome of MCI subtypes and aetiologies in the Goteborg MCI study. Journal of Neurology, Neurosurgery, & Psychiatry. 2010;81:541–546. [PubMed]
  • Oulhaj A, Wilcock GK, Smith AD, de Jager CA. Predicting the time of conversion to MCI in the elderly: role of verbal expression and learning. Neurology. 2009;73(18):1436–1442. [PMC free article] [PubMed]
  • Peres K, Chrysostome V, Fabrigoule C, Orgogozo JM, Dartigues JF, Barberger-Gateau P. Restriction in complex activities of daily living in MCI: impact on outcome. Neurology. 2006;67(3):461–466. [PubMed]
  • Petersen RC. Mild cognitive impairment as a diagnostic entity. Journal of Internal Medicine. 2004;256(3):183–194. [PubMed]
  • Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology. 1999;56(3):303–308. [PubMed]
  • Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, The Alzheimer’s Disease Cooperative Study Group Vitamin E and donepezil for the treatment of mild cognitive impairment. New England Journal of Medicine. 2005;352(23):2379–2388. [PubMed]
  • Porteus SD. Porteus Maze Test. Fifty year’s application. Psychological Corporation; New York: 1965.
  • Rapp MA, Reischies FM. Attention and executive control predict Alzheimer disease in late life: results from the Berlin Aging Study (BASE) American Journal of Geriatric Psychiatry. 2005;13(2):134–141. [PubMed]
  • Rascovsky K, Salmon DP, Hansen LA, Thal LJ, Galasko D. Disparate letter and semantic category fluency deficits in autopsy-confirmed frontotemporal dementia and Alzheimer’s disease. Neuropsychology. 2007;21(1):20–30. [PubMed]
  • Rasquin SM, Lodder J, Visser PJ, Lousberg R, Verhey FR. Predictive accuracy of MCI subtypes for Alzheimer’s disease and vascular dementia in subjects with mild cognitive impairment: a 2-year follow-up study. Dementia and Geriatric Cognitive Disorders. 2005;19(2-3):113–119. [PubMed]
  • Ravaglia G, Forti P, Maioli F, Martelli M, Servadei L, Brunetti N, Mariani E. Conversion of mild cognitive impairment to dementia: predictive role of mild cognitive impairment subtypes and vascular risk factors. Dementia and Geriatric Cognitive Disorders. 2006;21(1):51–58. [PubMed]
  • Ravaglia G, Forti P, Montesi F, Lucicesare A, Pisacane N, Rietti E, Mecocci P. Mild cognitive impairment: epidemiology and dementia risk in an elderly Italian population. Journal of the American Geriatric Society. 2008;56(1):51–58. [PubMed]
  • Reitan RM. Validity of the Trail Making Test as an indicator of organic brain damage. Perceptual and Motor Skills. 1958;8:271–276.
  • Riley KP, Snowdon DA, Desrosiers MF, Markesbery WR. Early life linguistic ability, late life cognitive function, and neuropathology: findings from the Nun Study. Neurobiology of Aging. 2005;26(3):341–347. [PubMed]
  • Robertson IH, Ward T, Ridgeway V, Nimmo-Smith I. The Test of Everyday Attention (TEA) Manual. Thames Valley Test Company; Bury St. Edmunds, England: 1994.
  • Rouleau I, Salmon DP, Butters N, Kennedy C, McGuire K. Quantitative and qualitative analyses of clock drawings in Alzheimer’s and Huntington’s disease. Brain and Cognition. 1992;18(1):70–87. [PubMed]
  • Rozzini L, Chilovi BV, Conti M, Bertoletti E, Delrio I, Trabucchi M, Padovani A. Conversion of amnestic mild cognitive impairment to dementia of Alzheimer type is independent to memory deterioration. International Journal Geriatric Psychiatry. 2007;22(12):1217–1222. [PubMed]
  • Salthouse TA, Atkinson TM, Berish DE. Executive functioning as a potential mediator of age-related cognitive decline in normal adults. Journal of Experimental Psychology: General. 2003;132(4):566–594. [PubMed]
  • Schretlen D, Bobholz JH, Brandt J. Development and psychometric properties of the Brief Test of Attention. Clinical Neuropsychologist. 1996;10(1):80–89.
  • Snowdon DA, Kemper SJ, Mortimer JA, Greiner LH, Wekstein DR, Markesbery WR. Linguistic ability in early life and cognitive function and Alzheimer’s disease in aate life: Findings from the Nun study. Journal of the American Medical Association. 1996;275(7):528–532. [PubMed]
  • Storandt M, Grant EA, Miller JP, Morris JC. Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. Neurology. 2006;67(3):467–473. [PubMed]
  • Thordike RL, Hagen EP, Sattler JM. The Stanford-Binet Intelligence Scale: Fourth Edition, Guide for Administration and Scoring. Riverside Publishing Company; Chicago, IL: 1986.
  • Tierney MC, Szalai JP, Snow WG, Fisher RH, Nores A, Nadon G, George-Hyslop PHS. Prediction of probable Alzheimer’s disease in memory-impaired patients: A prospective longitudinal study. Neurology. 1996;46(3):661–665. [PubMed]
  • Visser PJ, Kester A, Jolles J, Verhey F. Ten-year risk of dementia in subjects with mild cognitive impairment. Neurology. 2006;67(7):1201–1207. [PubMed]
  • Wechsler D. Weschler Memory Scale-Revised. The Psychological Corporation; San Antonio, TX: 1987.
  • Wilson BA, Alderman N, Burgess P, Emslie H, Evans J. Behavioural Assessment of the dysexecutive syndrome. Thames Valley Test Co.; Bury St Edmunds: 1996.
  • Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Petersen RC. Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. Journal of Internal Medicine. 2004;256(3):240–246. [PubMed]
  • Woods SP, Troster AI. Prodromal frontal/executive dysfunction predicts incident dementia in Parkinson’s disease. Journal of the International Neuropsychological Society. 2003;9(1):17–24. [PubMed]
  • Yaffe K, Petersen RC, Lindquist K, Kramer J, Miller B. Subtype of mild cognitive impairment and progression to dementia and death. Dementia and Geriatric Cognitive Disorders. 2006;22(4):312–319. [PubMed]
  • Yesavage J, Hoblyn J, Friedman L, Mumenthaler M, Schneider B, O’Hara R. Should one use medications in combination with cognitive training? If so, which ones? Journals of Gerontology Series B: Psychological Sciences and Social Sciences. 2007;62(1):11–18. [PubMed]
  • Zhang Y, Han B, Verhaeghen P, Nilsson L.-G.r. Executive functioning in older adults with mild cognitive impairment: MCI has effects on planning, but not on inhibition. Aging, Neuropsychology, and Cognition. 2007;14(6):557–570. [PubMed]